VK2735Research, Evidence & Safety Profile

VK2735 is a synthetic dual agonist peptide that activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It was developed by Viking Therapeutics (San Diego, CA) as an investigational treatment for obesity and metabolic disease.

The dual GLP-1/GIP mechanism places VK2735 in the same class as tirzepatide (Mounjaro/Zepbound), which is FDA-approved and demonstrated in Phase 3 trials to produce up to 22.5% body weight reduction. VK2735 is designed to occupy a similar mechanistic space but with a potentially distinct pharmacokinetic and tolerability profile.

As of April 2026, VK2735 is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for any medical use. It remains an investigational compound in clinical development. Phase 2 results for the subcutaneous formulation have been published. A Phase 3 maintenance dosing trial (VENTURE-M) completed enrollment in January 2026. An oral formulation is in parallel development.

Any individual considering use of VK2735 outside of a clinical trial should be aware that the compound is not approved, its full safety profile is not yet established, and its use is not supported by current medical guidelines.

VK2735 produces its metabolic effects by simultaneously activating two incretin hormone receptors:

• GLP-1 receptor agonism: GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food. GLP-1 receptor agonism stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, slows gastric emptying, and activates satiety centers in the hypothalamus — reducing appetite and caloric intake.
• GIP receptor agonism: GIP (glucose-dependent insulinotropic polypeptide) is a complementary incretin hormone secreted by intestinal K-cells. GIP receptor agonism amplifies glucose-stimulated insulin secretion and may contribute to the favorable lipid and adipose tissue metabolism seen with dual agonists. The synergistic combination of GLP-1 and GIP agonism appears to produce greater weight loss than either receptor pathway alone, as demonstrated in clinical comparisons between semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual).

The result of dual receptor activation is coordinated central appetite suppression, enhanced postprandial insulin response, and favorable effects on energy metabolism — all contributing to sustained caloric deficit and substantial body weight reduction.

The following potential benefits are based on Phase 2 human clinical trial data from the VENTURE trial (subcutaneous formulation). Phase 3 data from VENTURE-M is pending.

• Substantial weight loss: In the Phase 2 VENTURE trial (13-week treatment period), participants receiving the highest dose of subcutaneous VK2735 (2.4 mg weekly) achieved approximately 14.7% mean body weight reduction. At 52 weeks (including an off-drug observation period), changes in body weight were maintained in a subset of participants.
• Favorable cardiometabolic markers: Phase 2 data showed improvements in waist circumference, blood pressure, and fasting lipid profiles consistent with other GLP-1/GIP agonists in this drug class.
• Tolerability profile: Phase 2 data suggested a side effect profile broadly consistent with other incretin-based therapies, with gastrointestinal events (nausea, vomiting, constipation) being the most commonly reported adverse events.
• Oral formulation development: Viking Therapeutics is developing an oral version of VK2735, which, if successfully developed, would offer an administration advantage over injectable GLP-1/GIP agonists. Early Phase 1 oral data reported positive results.

It is important to note that Phase 2 trials are designed primarily to establish proof-of-concept and dose-ranging — not to provide the definitive efficacy and safety data required for regulatory approval. Phase 3 results are required before the full benefit-risk profile can be characterized.

The safety profile of VK2735 in Phase 2 trials showed adverse events consistent with the GLP-1 receptor agonist drug class. As Phase 3 data is not yet available, the full safety profile remains incompletely characterized.

Commonly reported adverse events in Phase 2 trials:

• Nausea (most common; typically dose-dependent and transient, occurring more frequently during dose escalation)
• Constipation
• Vomiting
• Diarrhea
• Injection site reactions (with subcutaneous formulation)

Theoretical and class-related safety considerations:

• Pancreatitis: GLP-1 receptor agonists as a class carry a warning for pancreatitis risk, including hemorrhagic and necrotizing pancreatitis. Patients with a history of pancreatitis are typically excluded from trials.
• Thyroid C-cell tumors: Rodent studies with GLP-1 agonists have shown thyroid C-cell tumor formation. This effect has not been established in humans, but GLP-1 agonists carry class-level warnings for this and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Lean mass reduction: As with other GLP-1/GIP agonists, significant caloric restriction during treatment may result in lean body mass (muscle) loss alongside fat loss. The magnitude depends on protein intake and resistance training.
• Hypoglycemia: Risk is low when used alone in non-diabetic populations; risk increases when combined with insulin or sulfonylurea medications.

VK2735 is an investigational compound and should not be used outside of properly conducted clinical trials or without medical supervision.

Disclaimer: VK2735 is an investigational compound with no regulatory approval. It is not available from licensed pharmacies, and no medical body currently recommends it. The doses described below are those used in published and ongoing clinical trials run by Viking Therapeutics — they are reported for educational context only and should not be interpreted as guidance for personal use.

Doses used in clinical development:

• Phase 2 VENTURE trial (subcutaneous): Weekly subcutaneous doses ranging from 0.5 mg to 2.4 mg over a 13-week treatment period. The 2.4 mg weekly dose produced the largest placebo-adjusted weight reduction (approximately 13.1%). Dose titration from lower starting doses was used to mitigate gastrointestinal side effects, consistent with standard incretin-class titration practice.
• Phase 3 VENTURE-M trial (subcutaneous, maintenance): Viking Therapeutics completed enrollment of the Phase 3 maintenance dosing study in January 2026. Trial design is focused on weekly maintenance dosing after an initial lead-in induction phase; specific dose details are published in the trial protocol on ClinicalTrials.gov.
• Oral formulation (Phase 1): Early Phase 1 data on an oral tablet formulation have been reported by Viking Therapeutics. Dose range and bioavailability characteristics for the oral formulation differ from the subcutaneous formulation and are still under investigation.

Clinical trial dose escalation schedules are protocol-controlled and supervised by trial investigators. The compound is not currently available outside of registered clinical trial sites, and any other source offering VK2735 cannot be verified for identity or purity. Anyone interested in participating in a VK2735 trial should search ClinicalTrials.gov for active studies and consult with a physician before enrolling.

VK2735 has completed Phase 2 clinical development for subcutaneous administration and is actively in Phase 3 development as of April 2026.

VENTURE Trial (Phase 2, Subcutaneous)

The VENTURE trial was a randomized, double-blind, placebo-controlled Phase 2 study evaluating subcutaneous VK2735 in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI 27–29.9 kg/m²) with at least one weight-related comorbidity. Participants were randomized to receive weekly subcutaneous injections of VK2735 (doses ranging from 0.5 mg to 2.4 mg) or placebo over 13 weeks, with a post-treatment follow-up period extending to 52 weeks.

Key results:

• Mean placebo-adjusted weight loss at 13 weeks: approximately 13.1% at the 2.4 mg dose
• Treatment was generally well tolerated; most adverse events were mild-to-moderate and gastrointestinal in nature
• No serious safety signals distinct from the GLP-1/GIP class were identified

These results were published and formed the basis for Phase 3 advancement.

VENTURE-M (Phase 3, Maintenance)

Viking Therapeutics announced completion of enrollment for VENTURE-M, the Phase 3 maintenance dosing study of subcutaneous VK2735, on January 8, 2026. VENTURE-M is designed to evaluate the long-term efficacy and safety of VK2735 and, specifically, the durability of weight loss with continued dosing versus discontinuation. Results are expected in 2026–2027.

Oral Formulation Development

A Phase 1 clinical trial for an oral formulation of VK2735 demonstrated positive pharmacokinetic results, according to Viking Therapeutics. Phase 2 development of the oral formulation is underway.

Limitations of the current evidence base:

• Phase 2 data only for the primary subcutaneous formulation — Phase 3 confirmatory results have not been published
• Long-term safety data (beyond 52 weeks) is not yet available
• No head-to-head trials comparing VK2735 directly to tirzepatide or semaglutide have been completed
• The oral formulation's bioavailability and clinical efficacy relative to the subcutaneous formulation remains under investigation

As of April 2026, VK2735 is an investigational compound with no regulatory approval from any health authority including the FDA, EMA, or Health Canada.

Viking Therapeutics has not yet submitted a New Drug Application (NDA) or Biologics License Application (BLA) for VK2735. Regulatory submission would follow review of the complete Phase 3 dataset, which is anticipated after VENTURE-M and related trials read out in 2026–2027.

The compound is not available through licensed pharmacies, compounding pharmacies, or any legitimate commercial channels. It should not be confused with FDA-approved GLP-1/GIP agonists such as tirzepatide (Mounjaro/Zepbound). Research chemical suppliers that claim to offer VK2735 are operating outside clinical and regulatory frameworks; the purity, identity, and safety of such products cannot be verified.